<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248612</url>
  </required_header>
  <id_info>
    <org_study_id>H-22529</org_study_id>
    <secondary_id>R01AA013727-01A1</secondary_id>
    <nct_id>NCT00248612</nct_id>
  </id_info>
  <brief_title>Psychosocial and Medication Treatment for Anxiety in Alcoholism</brief_title>
  <official_title>CBT And Venlafaxine Treatments For Anxiety In Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed project is written as a &quot;typical clinical practice&quot; test and is a
      fully-controlled trial of a combined anxiety-focused CBT and pharmacotherapy (venlafaxine;
      CBT-VEN) delivered for patients with comorbid alcohol-use and anxiety disorders. The CBT and
      pharmacotherapy will be contrasted with relaxation training and placebo medication. One
      hundred and eighty participants will be recruited and, subsequent to a platform of outpatient
      treatment for alcoholism, will be randomly assigned to a 12-week treatment condition. All
      treatment conditions will begin with a 1-week placebo run-in, after which participants will
      begin a trial of venlafaxine or placebo. The treatments will conclude with a 2-week
      medication/placebo taper. Follow-up assessments will be conducted at post-treatment and at 3,
      6, 9, and 12-months. The long-term objectives of this research are to develop a real-world
      combination of psychosocial and pharmacological treatments for patients with comorbid
      alcohol-use and anxiety disorders that compromise prognosis, and to evaluate the
      effectiveness of combined psychosocial and pharmacological treatments that target anxiety
      among patients with this comorbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Difficulties in anxiety management are frequent causes of relapse to alcohol use. Empirical
      data support the role of anxiety in alcohol relapse, and both psychosocial and
      pharmacological treatments for alcohol problems increasingly address the role of negative
      affect in alcohol-use disorders. Due to the lack of large, well-controlled treatment outcome
      trials, the optimal treatment (or combination of treatments) remains unknown. Real world
      practice in the treatment of alcohol-use disorders frequently begins with brief
      detoxification and stabilization, and is often followed by some combination of CBT and
      pharmacotherapy for patients complaining of mood difficulties while attempting early
      abstinence from alcohol.

      The purpose of the present study is to evaluate the relative benefits of psychosocial and
      psychopharmacological therapy for the treatment of co-morbid anxiety and alcohol dependence
      among patients attempting early abstinence from alcohol. We will address the following four
      questions:

        1. During the course of intervention, is treatment of anxiety disorders with combined
           treatments of established utility (among non-alcohol-use-disordered patients) superior
           in managing both return to drinking and anxiety symptoms than either monotherapy, or a
           fully inactive control treatment?

        2. During the follow-up period, will patients who received the combined active treatments
           fare better in maintaining abstinence relative to the single active treatments, and
           those in the control condition?

        3. What psychosocial variables (such as increases or lapses to elevated anxiety) mediate
           return to pre-treatment levels of alcohol use?

        4. Will baseline indices of alcohol dependence and anxiety disorder severity moderate the
           relationship between treatment and outcome during both the acute and follow-up phases of
           the study?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression Scale-I (CGI-I)</measure>
    <time_frame>Session 1 (Baseline) , Session 8 (8 weeks of treatment), Session 11 (11 weeks of treatment)</time_frame>
    <description>Global improvement of alcohol dependence: Rate the total improvement in the participant's alcohol dependence symptoms whether or not, in your judgment, it is due entirely to treatment. Compared to his/her admission to the project, how much has s/he changed?
(1-Not assessed, first rating, 2-Very much improved, 3-Much improved, 4-Minimally improved, 5-Unchanged, 6-Minimally worse, 7-Much worse, 8-Very much worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression Scale-S (CGI-S)</measure>
    <time_frame>1 (Baseline) , Session 8 (8 weeks of treatment), Session 11 (11 weeks of treatment)</time_frame>
    <description>Global severity of alcohol dependence: Considering your total clinical experience with the alcohol dependent population how severe are his/her alcohol dependence symptoms at this time?
(1-Normal, no symptoms, 2-Borderline symptoms, 3-Mild symptoms, 4-Moderate symptoms, 5-Marked symptoms, 6-Severe symptoms, 7-Among the most extreme symptoms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Craving Desire Scale (CDS)</measure>
    <time_frame>1 (Baseline) , Session 8 (8 weeks of treatment), Session 11 (11 weeks of treatment)</time_frame>
    <description>The Craving Desire Scale (CDS) is a 3-item scale (&quot;1. I do want to drink now&quot;, &quot;2. I crave a drink right now&quot;, 3. &quot;I have a desire for a drink right now&quot;) used to identify the degree of current alcohol craving, with responses provided on a Likert scale of 1-7: with 1 meaning strongly disagree, and 7 meaning strongly agree to each of the 3 items. Total scores can range from 3 to 21 with higher scores indicating greater craving for alcohol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Abstinent</measure>
    <time_frame>Session 8 (8 weeks of treatment)</time_frame>
    <description>Abstaining from the consumption of intoxicating beverages.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Completion</measure>
    <time_frame>12 months</time_frame>
    <description>The number and percent of participants that completed the treatment in each arm of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Compliance Rates</measure>
    <time_frame>12 months</time_frame>
    <description>The medication compliance rate is the percentage of participants in each study arm who took their medication based on pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DASS Stress Subscale Score</measure>
    <time_frame>Session 1 (baseline), Session 11 (11 weeks of treatment)</time_frame>
    <description>DASS (Depression Anxiety Stress Scales) assesses depression, anxiety and stress responses. Each of the three DASS scales contains 14 items, divided into subscales of 2-5 items with similar content. The stress subscale was used which assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient. Subjects are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Stress scores can range form 0-56 with 0-14=normal, 15-18=mild, 19-25=moderate, 26-33=severe. and 34+=extremely severe stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A Scale</measure>
    <time_frame>Session 1 (baseline), Session 8 (8 weeks of treatment)</time_frame>
    <description>The Hamilton Anxiety Rating Scale (HAM-A) is a psychological questionnaire used by clinicians to rate the severity of a patient's anxiety. The HAM-A probes 14 parameters each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. total scores can range from 0 to 56.where &lt;17 indicates mild anxiety, 18-24 moderate anxiety and 25-30 severe anxiety. Higher scores reflect more anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-D Scale</measure>
    <time_frame>Session 1 (baseline), Session 8 (8 weeks of treatment)</time_frame>
    <description>HAM-D (Hamilton Rating Scale for Depression) is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The scoring is based on 17 items. Eight of the items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored on a 3 point scale from 0-2 where 0=none or absent and 2= severe. The total scores for the HAM-D can range from 0 to 50. The total scores are interpreted as: 0-7=normal, 8-13=mild, 14-18= moderate, 19-22= severe, and 23+=very severe depression. The higher the score the more severe the participant's depression.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Alcohol-Related Disorders</condition>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Venlafaxine &amp; CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; CBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine &amp; PMR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; PMR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
    <arm_group_label>Venlafaxine &amp; CBT</arm_group_label>
    <arm_group_label>Venlafaxine &amp; PMR</arm_group_label>
    <other_name>Effexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT</intervention_name>
    <description>CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
    <arm_group_label>Venlafaxine &amp; CBT</arm_group_label>
    <arm_group_label>Placebo &amp; CBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Progressive muscle relaxation therapy (PMR)</intervention_name>
    <description>For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.</description>
    <arm_group_label>Venlafaxine &amp; PMR</arm_group_label>
    <arm_group_label>Placebo &amp; PMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo medication</intervention_name>
    <description>For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.</description>
    <arm_group_label>Placebo &amp; CBT</arm_group_label>
    <arm_group_label>Placebo &amp; PMR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be English-speaking males or females

          -  Participants must be between 18 and 65 years old

          -  Meet criteria for DSM-IV diagnosis of alcohol abuse or dependence

          -  Meet criteria for Panic disorder, Social Phobia or Generalized Anxiety Disorder

          -  Physically able to attend sessions at the Counseling Center

          -  Able to read and write

          -  Able to complete the structured interview and self-report assessment packet

          -  Able to attend all treatment sessions and follow-up assessments

          -  Able to sign a witnessed informed consent form

          -  Participants express a desire to completely stop drinking alcohol or reduce alcohol
             consumption with the possible long-term goal of abstinence

        Exclusion Criteria:

          -  Meet DSM-IV diagnostic criteria for bipolar disorder, schizophrenia, bulimia/anorexia,
             or dementia

          -  Currently taking anti-craving agents (e.g. Naltrexone, methadone)

          -  Currently taking medication that has clinically significant interactions with
             venlafaxine

          -  Previous use of venlafaxine

          -  Currently taking other antidepressant medications

          -  Currently taking medication known to decrease anxiety or alcohol consumption (e.g.
             antabuse)

          -  Currently prescribed medications with known abuse potential (e.g., subjects on opioid
             agonist therapy)

          -  Currently prescribed medications as a sleep aid (e.g. Ambien)

          -  Currently taking herbal supplements that have been shown to interact with venlafaxine
             or affect anxiety symptoms

          -  Currently pregnant, breastfeeding, plans of becoming pregnant during the course of the
             study, or not using medically acceptable form of birth control (oral contraceptives,
             barrier [diaphragm or condom] with spermicide, intrauterine progesterone contraceptive
             system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection).

          -  Planning to relocate out-of-state within four months of protocol initiation

          -  History of psychotic symptoms within the past 30 days

          -  Experiencing severe symptoms of depression or have engaged in suicidal behaviors
             within the past 30 days

          -  Medical contraindications to the use of venlafaxine [severe renal disease, cirrhosis,
             uncontrolled blood pressure, recent cardiovascular problems (e.g., heart attack), and
             seizure disorders; currently taking a monoamine oxidase inhibitor, MAOI]

          -  Self-reported anxiety less than 15 on the Hamilton Rating Scale for Anxiety

          -  Participant is a member of the same household of another subject already participating
             in the study

          -  Participant is legally mandated (e.g., to avoid incarceration, monetary or other
             penalties, etc.) to participate in an alcohol treatment program

          -  Participant has a current or recent (past 30 days) DSM-IV diagnosis of other substance
             abuse or dependence, with the exception of nicotine, marijuana, and caffeine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenic Ciraulo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Anxiety and Related Disorders</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>July 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2017</results_first_posted>
  <last_update_submitted>January 21, 2018</last_update_submitted>
  <last_update_submitted_qc>January 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venlafaxine</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Anxiety Disorders</keyword>
  <keyword>Alcohol-Use Disorders</keyword>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Cognitive Behavioral Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Following telephone screening (n=950), 162 eligible subjects completed an in-clinic baseline assessment #1 to determine eligibility for inclusion in the study.</recruitment_details>
      <pre_assignment_details>Once subjects achieved the four day period of abstinence they completed a second baseline assessment in which eligibility was re-assessed. 81 Eligible subjects were then randomized into the four study arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Venlafaxine &amp; CBT</title>
          <description>Venlafaxine (Effexor XR): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper. They will also receive tailored cognitive behavioral training (CBT)</description>
        </group>
        <group group_id="P2">
          <title>Placebo &amp; CBT</title>
          <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
        </group>
        <group group_id="P3">
          <title>Venlafaxine &amp; PMR</title>
          <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
        </group>
        <group group_id="P4">
          <title>Placebo &amp; PMR</title>
          <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Venlafaxine &amp; CBT</title>
          <description>Venlafaxine (Effexor XR) and CBT (Cognitive Behavioral therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
        </group>
        <group group_id="B2">
          <title>Placebo &amp; CBT</title>
          <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
        </group>
        <group group_id="B3">
          <title>Venlafaxine &amp; PMR</title>
          <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
        </group>
        <group group_id="B4">
          <title>Placebo &amp; PMR</title>
          <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinking status</title>
          <description>Drinking status was measured for the 90 day long pre-screening period by calculating the mean percent and standard deviation of the days drinking and of the days heavy drinking</description>
          <units>percent of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>percent days drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="24.5"/>
                    <measurement group_id="B2" value="76.0" spread="25.6"/>
                    <measurement group_id="B3" value="88.0" spread="12.7"/>
                    <measurement group_id="B4" value="76.5" spread="25.8"/>
                    <measurement group_id="B5" value="77" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percent days heavy drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="28.0"/>
                    <measurement group_id="B2" value="59.1" spread="33.7"/>
                    <measurement group_id="B3" value="76.9" spread="19.1"/>
                    <measurement group_id="B4" value="67.2" spread="28.6"/>
                    <measurement group_id="B5" value="65.6" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADS Scores</title>
          <description>The ADS provides a quantitative measure of the severity of alcohol dependence consistent with the concept of the alcohol dependence syndrome. The 25 items cover alcohol withdrawal symptoms, impaired control over drinking, awareness of a compulsion to drink, increased tolerance to alcohol, and salience of drink-seeking behavior. Scores range from 0-47.0= no alcohol dependence, 1-13=low, 14-21 =intermediate, 22-30= substantial and 31-47= severe level of alcohol dependence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.0" spread="7.6"/>
                    <measurement group_id="B2" value="15.8" spread="7.7"/>
                    <measurement group_id="B3" value="16.6" spread="6.6"/>
                    <measurement group_id="B4" value="16.1" spread="5.9"/>
                    <measurement group_id="B5" value="15.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks per day</title>
          <description>The average number of drinks per day was obtained by taking the mean of the number of drinks each day for the 90 day long pre-screening period.</description>
          <units>number of drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="6.5"/>
                    <measurement group_id="B2" value="7.0" spread="4.6"/>
                    <measurement group_id="B3" value="9.6" spread="4.3"/>
                    <measurement group_id="B4" value="9.7" spread="7.5"/>
                    <measurement group_id="B5" value="8.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression Scale-I (CGI-I)</title>
        <description>Global improvement of alcohol dependence: Rate the total improvement in the participant’s alcohol dependence symptoms whether or not, in your judgment, it is due entirely to treatment. Compared to his/her admission to the project, how much has s/he changed?
(1-Not assessed, first rating, 2-Very much improved, 3-Much improved, 4-Minimally improved, 5-Unchanged, 6-Minimally worse, 7-Much worse, 8-Very much worse)</description>
        <time_frame>Session 1 (Baseline) , Session 8 (8 weeks of treatment), Session 11 (11 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale-I (CGI-I)</title>
          <description>Global improvement of alcohol dependence: Rate the total improvement in the participant’s alcohol dependence symptoms whether or not, in your judgment, it is due entirely to treatment. Compared to his/her admission to the project, how much has s/he changed?
(1-Not assessed, first rating, 2-Very much improved, 3-Much improved, 4-Minimally improved, 5-Unchanged, 6-Minimally worse, 7-Much worse, 8-Very much worse)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 CGI-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="1.34"/>
                    <measurement group_id="O2" value="3.81" spread="1.21"/>
                    <measurement group_id="O3" value="3.86" spread="1.10"/>
                    <measurement group_id="O4" value="4.05" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 8 CGI-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.38"/>
                    <measurement group_id="O2" value="3.13" spread="0.89"/>
                    <measurement group_id="O3" value="3.50" spread="1.09"/>
                    <measurement group_id="O4" value="3.53" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 11 CGI-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="1.30"/>
                    <measurement group_id="O2" value="2.61" spread="0.78"/>
                    <measurement group_id="O3" value="3.00" spread="1.15"/>
                    <measurement group_id="O4" value="2.92" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression Scale-S (CGI-S)</title>
        <description>Global severity of alcohol dependence: Considering your total clinical experience with the alcohol dependent population how severe are his/her alcohol dependence symptoms at this time?
(1-Normal, no symptoms, 2-Borderline symptoms, 3-Mild symptoms, 4-Moderate symptoms, 5-Marked symptoms, 6-Severe symptoms, 7-Among the most extreme symptoms)</description>
        <time_frame>1 (Baseline) , Session 8 (8 weeks of treatment), Session 11 (11 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale-S (CGI-S)</title>
          <description>Global severity of alcohol dependence: Considering your total clinical experience with the alcohol dependent population how severe are his/her alcohol dependence symptoms at this time?
(1-Normal, no symptoms, 2-Borderline symptoms, 3-Mild symptoms, 4-Moderate symptoms, 5-Marked symptoms, 6-Severe symptoms, 7-Among the most extreme symptoms)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 CGI-S</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="1.24"/>
                    <measurement group_id="O2" value="3.76" spread="0.89"/>
                    <measurement group_id="O3" value="3.93" spread="0.92"/>
                    <measurement group_id="O4" value="4.18" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 8 CGI-S</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="1.49"/>
                    <measurement group_id="O2" value="2.88" spread="1.26"/>
                    <measurement group_id="O3" value="3.25" spread="1.42"/>
                    <measurement group_id="O4" value="3.40" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 11 CGI-S</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.88"/>
                    <measurement group_id="O2" value="2.53" spread="1.18"/>
                    <measurement group_id="O3" value="2.60" spread="1.51"/>
                    <measurement group_id="O4" value="2.85" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Craving Desire Scale (CDS)</title>
        <description>The Craving Desire Scale (CDS) is a 3-item scale (&quot;1. I do want to drink now”, “2. I crave a drink right now”, 3. “I have a desire for a drink right now”) used to identify the degree of current alcohol craving, with responses provided on a Likert scale of 1-7: with 1 meaning strongly disagree, and 7 meaning strongly agree to each of the 3 items. Total scores can range from 3 to 21 with higher scores indicating greater craving for alcohol.</description>
        <time_frame>1 (Baseline) , Session 8 (8 weeks of treatment), Session 11 (11 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Craving Desire Scale (CDS)</title>
          <description>The Craving Desire Scale (CDS) is a 3-item scale (&quot;1. I do want to drink now”, “2. I crave a drink right now”, 3. “I have a desire for a drink right now”) used to identify the degree of current alcohol craving, with responses provided on a Likert scale of 1-7: with 1 meaning strongly disagree, and 7 meaning strongly agree to each of the 3 items. Total scores can range from 3 to 21 with higher scores indicating greater craving for alcohol.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 CDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" spread="6.03"/>
                    <measurement group_id="O2" value="8.14" spread="5.02"/>
                    <measurement group_id="O3" value="8.21" spread="5.94"/>
                    <measurement group_id="O4" value="7.55" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 8 CDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" spread="5.28"/>
                    <measurement group_id="O2" value="7.41" spread="5.06"/>
                    <measurement group_id="O3" value="4.45" spread="1.75"/>
                    <measurement group_id="O4" value="5.56" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 11 CDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="1.94"/>
                    <measurement group_id="O2" value="6.11" spread="4.76"/>
                    <measurement group_id="O3" value="5.10" spread="2.08"/>
                    <measurement group_id="O4" value="4.25" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Abstinent</title>
        <description>Abstaining from the consumption of intoxicating beverages.</description>
        <time_frame>Session 8 (8 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR) and CBT (Cognitive Behavioral therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abstinent</title>
          <description>Abstaining from the consumption of intoxicating beverages.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Completion</title>
        <description>The number and percent of participants that completed the treatment in each arm of the study.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR) and CBT (Cognitive Behavioral therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Completion</title>
          <description>The number and percent of participants that completed the treatment in each arm of the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Compliance Rates</title>
        <description>The medication compliance rate is the percentage of participants in each study arm who took their medication based on pill counts.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Compliance Rates</title>
          <description>The medication compliance rate is the percentage of participants in each study arm who took their medication based on pill counts.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.89"/>
                    <measurement group_id="O2" value="97.06"/>
                    <measurement group_id="O3" value="88.70"/>
                    <measurement group_id="O4" value="95.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DASS Stress Subscale Score</title>
        <description>DASS (Depression Anxiety Stress Scales) assesses depression, anxiety and stress responses. Each of the three DASS scales contains 14 items, divided into subscales of 2-5 items with similar content. The stress subscale was used which assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient. Subjects are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Stress scores can range form 0-56 with 0-14=normal, 15-18=mild, 19-25=moderate, 26-33=severe. and 34+=extremely severe stress.</description>
        <time_frame>Session 1 (baseline), Session 11 (11 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR) and CBT (Cognitive Behavioral therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>DASS Stress Subscale Score</title>
          <description>DASS (Depression Anxiety Stress Scales) assesses depression, anxiety and stress responses. Each of the three DASS scales contains 14 items, divided into subscales of 2-5 items with similar content. The stress subscale was used which assesses difficulty relaxing, nervous arousal, and being easily upset/agitated, irritable/over-reactive and impatient. Subjects are asked to use 4-point severity/frequency scales to rate the extent to which they have experienced each state over the past week. Stress scores can range form 0-56 with 0-14=normal, 15-18=mild, 19-25=moderate, 26-33=severe. and 34+=extremely severe stress.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 DASS stress subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="7.6"/>
                    <measurement group_id="O2" value="19.2" spread="9.1"/>
                    <measurement group_id="O3" value="21.5" spread="11.3"/>
                    <measurement group_id="O4" value="16.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 11 DASS stress subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="4.6"/>
                    <measurement group_id="O2" value="9.6" spread="7.9"/>
                    <measurement group_id="O3" value="4.1" spread="7.9"/>
                    <measurement group_id="O4" value="11.2" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAM-A Scale</title>
        <description>The Hamilton Anxiety Rating Scale (HAM-A) is a psychological questionnaire used by clinicians to rate the severity of a patient's anxiety. The HAM-A probes 14 parameters each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. total scores can range from 0 to 56.where &lt;17 indicates mild anxiety, 18–24 moderate anxiety and 25–30 severe anxiety. Higher scores reflect more anxiety.</description>
        <time_frame>Session 1 (baseline), Session 8 (8 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR) and CBT (Cognitive Behavioral therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>HAM-A Scale</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) is a psychological questionnaire used by clinicians to rate the severity of a patient's anxiety. The HAM-A probes 14 parameters each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. total scores can range from 0 to 56.where &lt;17 indicates mild anxiety, 18–24 moderate anxiety and 25–30 severe anxiety. Higher scores reflect more anxiety.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 HAM-A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="5.9"/>
                    <measurement group_id="O2" value="14.2" spread="7.3"/>
                    <measurement group_id="O3" value="16.5" spread="6.8"/>
                    <measurement group_id="O4" value="12.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 8 HAM-A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="6.9"/>
                    <measurement group_id="O2" value="9.1" spread="5.5"/>
                    <measurement group_id="O3" value="7.9" spread="5.5"/>
                    <measurement group_id="O4" value="9.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAM-D Scale</title>
        <description>HAM-D (Hamilton Rating Scale for Depression) is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The scoring is based on 17 items. Eight of the items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored on a 3 point scale from 0-2 where 0=none or absent and 2= severe. The total scores for the HAM-D can range from 0 to 50. The total scores are interpreted as: 0-7=normal, 8-13=mild, 14-18= moderate, 19-22= severe, and 23+=very severe depression. The higher the score the more severe the participant's depression.</description>
        <time_frame>Session 1 (baseline), Session 8 (8 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Venlafaxine &amp; CBT</title>
            <description>Venlafaxine (Effexor XR) and CBT (Cognitive Behavioral therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
          </group>
          <group group_id="O2">
            <title>Placebo &amp; CBT</title>
            <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
          </group>
          <group group_id="O3">
            <title>Venlafaxine &amp; PMR</title>
            <description>Venlafaxine and PMR (progressive muscle relaxation therapy).</description>
          </group>
          <group group_id="O4">
            <title>Placebo &amp; PMR</title>
            <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
          </group>
        </group_list>
        <measure>
          <title>HAM-D Scale</title>
          <description>HAM-D (Hamilton Rating Scale for Depression) is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The scoring is based on 17 items. Eight of the items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored on a 3 point scale from 0-2 where 0=none or absent and 2= severe. The total scores for the HAM-D can range from 0 to 50. The total scores are interpreted as: 0-7=normal, 8-13=mild, 14-18= moderate, 19-22= severe, and 23+=very severe depression. The higher the score the more severe the participant's depression.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 HAM-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="5.7"/>
                    <measurement group_id="O2" value="11.7" spread="6.0"/>
                    <measurement group_id="O3" value="13.0" spread="7.2"/>
                    <measurement group_id="O4" value="13.6" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 8 HAM-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="6.6"/>
                    <measurement group_id="O2" value="8.5" spread="4.6"/>
                    <measurement group_id="O3" value="5.9" spread="5.6"/>
                    <measurement group_id="O4" value="10" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Venlafaxine &amp; CBT</title>
          <description>Venlafaxine (Effexor XR): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.</description>
        </group>
        <group group_id="E2">
          <title>Placebo &amp; CBT</title>
          <description>Placebo and CBT (Cognitive Behavioral Therapy): Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.</description>
        </group>
        <group group_id="E3">
          <title>Venlafaxine &amp; PMR</title>
          <description>Venlafaxine medication and PMR (progressive muscle relaxation therapy).</description>
        </group>
        <group group_id="E4">
          <title>Placebo &amp; PMR</title>
          <description>Placebo medication and PMR (progressive muscle relaxation therapy)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>elevated blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>profuse sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>agitation/restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small size of treatment groups leading to diminished meaningful difference between comparison groups at follow-up; Failure of randomization leading to unequal number of subjects in each treatment group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Todd J. Farchione, PhD</name_or_title>
      <organization>Center for Anxiety and Related Disorders at Boston University</organization>
      <phone>617 353 9610</phone>
      <email>tfarchio@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

